CELZ earnings analysis
What we found in CELZ's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or risk-factor section, so revenue, margins, EPS, liquidity, working-capital trends, free cash flow, and segment performance cannot be assessed from the available text. No quantitative guidance is provided. Management reported effective disclosure controls in Item 4, while Item 1 retains a general warning regarding potential litigation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls assessed as effective
- In Item 4, management concluded that disclosure controls and procedures were effective as of the end of the reporting period. The filing also states there were no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Unquantified litigation exposure
- Item 1 states that the company may become involved in various lawsuits and legal proceedings and warns that an adverse result could harm the business. The filing provides no quantified litigation exposure.
What they said about what is next.
No quantitative outlook or forward guidance is provided in the supplied 10-Q extract. The extract contains no revenue, EPS, liquidity, or capital-spending outlook.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 8, 2026
- Creative Medical Technology Holdings, Inc. reported no revenue for Q1 2026, a significant drop from $3,000 in Q1 2025, resulting in a gross profit decline to $0. Operating loss narrowed slightly to $1,459,153 from…
- 10-K · April 24, 2026
- The 2025 Form 10-K/A shows Creative Medical is continuing to invest in its cell-therapy platform (notably a $5,000,000 research-tools acquisition recorded as R&D) while retaining a small public footprint (3,696,668…
- 10-K · March 20, 2026
- Creative Medical (CELZ) is a clinical-stage regenerative-therapy company with multiple cell therapy platforms (ImmCelz, AlloStem, iPScelz) and limited commercial products (CaverStem/FemCelz). The 2025 10-K shows…
- 10-Q · November 7, 2025
- Creative Medical reported Q3 (three months ended September 30, 2025) results showing zero revenue and a GAAP net loss of $1,235,934, or $(0.48) per share. Cash declined modestly to $5.38M at September 30, 2025, and the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CELZ makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever